major factor critical potential effectiveness 212bi radioimmunotherapy design antibodies stable vivo chelate bind radiometal firmly minimize release radionuclide monoclonal complex present study examines member new class polyamine carboxylate chelating compounds dota ligands conjugating radiometal ions antibody biocompatibility stability assessed monoclonal antibody directed human interleukin NUMBER receptors scientific basis clinical use antibody radioimmunotherapy resting normal cells express interleukin NUMBER receptor receptor expressed surface certain neoplasms activated select autoimmune diseases allograft rejection examined impact labeling procedure presence chelate dota antibody bioavailability survival studied capacity complex retain radiobismuth coupling dota antibody adding biiii antibody did disturb antibody immunoreactivity vitro binding studies addition analyzed vivo studies dummy labeled nonradioactive bismuth showed pharmacokinetics tissue distribution identical antibody modified dota charged radioactive bismuth showed pharmacokinetics identical radioiodinated dotaantibody suggesting little premature release radioactive bismuth antibody complex early therapeutically relevant time points NUMBER h NUMBER h significant preferential accumulation bismuth organ time point range therapeutic delayed excretion bismuth reticuloendothelial tissues relative radioiodine catabolized antibody excretion catabolized apparent approximately NUMBER day marked renal accumulation typical free bismuth ion compatibility dota conjugation antibody bioactivity stability radioactive bismuth complex vivo provide important preclinical validation potential utility new chelating agent 212bi monoclonal antibody radioimmunotherapy humans alpha emitter radiometal chelated antibody chelate anti tac t cells antibody chelate dota coupled dota antibody dota anti tac dummy labeled NUMBER day dota bismuth t1 NUMBER